151 – 160 of 320
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease
- Contribution to journal › Article
-
Mark
The association between indicators of health and housing in people with Parkinson's disease
- Contribution to journal › Article
-
Mark
Brain repair and reprogramming : the route to clinical translation
- Contribution to journal › Scientific review
-
Mark
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
- Contribution to journal › Article
-
Mark
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease : An open-label prospective observational study of effectiveness, tolerability and healthcare costs
- Contribution to journal › Article
-
Mark
Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists
- Contribution to journal › Article
-
Mark
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model
- Contribution to journal › Article
-
Mark
Pathogenic effects of alpha-synuclein: modifications and toxicity
(2016)
- Thesis › Doctoral thesis (compilation)
-
Mark
Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis
- Contribution to journal › Scientific review
-
Mark
How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
- Contribution to journal › Scientific review
